New Waldenstrom’s drug shows sustained benefit at two years

9 abril 2015

Ibrutinib, a newly approved drug for Waldenstrom’s Macroglobulinemia, continues to control the rare blood cancer, with 95 percent of patients surviving for two years, research concludes. The disease stems from an abnormality in B lymphocytes in the bone marrow causing them to overproduce IgM, an immunoglobulin protein that thickens the blood; patients may experience bleeding, dizziness, headaches, weight loss, bruising and nerve damage.